Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A naturally occurring nonapeptide produced in the hypothalamus and released by the pituitary gland. Known as the 'bonding hormone' for its role in social bonding, trust, and attachment. Also has established medical uses in obstetrics. Growing interest in intranasal oxytocin for social anxiety, autism spectrum disorder, and relationship enhancement.
A synthetic heptapeptide analog of ACTH(4-10) developed in Russia, where it has been used clinically for decades to treat cerebral ischemia and cognitive impairment. Growing interest in the West for nootropic and neuroprotective applications.
Binds to oxytocin receptors throughout the brain and body. In the brain, modulates the limbic system to reduce fear and increase trust and social engagement. Peripherally, stimulates uterine contractions (obstetric use) and milk ejection. Intranasal delivery allows direct access to the brain via the olfactory pathway.
Activates BDNF (brain-derived neurotrophic factor) and its receptor TrkB, promoting neuronal survival, synaptic plasticity, and cognitive function. Also modulates serotonergic, dopaminergic, and adrenergic systems. Reduces oxidative stress and neuroinflammation.
- Social anxiety and social bonding
- Autism spectrum disorder support (investigational)
- Relationship and intimacy enhancement
- Postpartum bonding
- Labor induction (FDA-approved obstetric use)
- Cognitive enhancement and focus
- Neuroprotection after stroke or ischemia
- Anxiety and depression support
- ADHD symptom management
- Memory and learning improvement
- Potential for emotional dependency with frequent use
- May amplify negative social emotions as well as positive ones
- Headaches and nausea
- Intranasal use has limited long-term safety data
- Contraindicated in certain obstetric situations
- Limited Western clinical trial data
- Nasal spray form may cause irritation
- Potential stimulant-like effects
- Headaches reported
- Long-term safety profile unknown in Western populations
FDA-approved as Pitocin for obstetric use (labor induction, postpartum hemorrhage). Intranasal oxytocin for psychiatric and social indications is investigational — not FDA-approved for these uses. Available through compounding pharmacies with a prescription for off-label intranasal use.
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 24, 2026. Has extensive clinical use in Russia for cerebral ischemia and trigeminal neuralgia, but limited US clinical trial data. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
PCAC: July 24, 2026
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.